

New Generation Non-Soda Lime Absorbents: Factors Affecting Patient Safety During Inhalational Anaesthesia; *in vitro* evaluation of AMSORB[®] PLUS and LoFloSorb[®]

Magee, C.D. PhD§; Turbitt, D. PhD

§Technical Director, Armstrong Medical Limited, Wattstown Business Park, Newbridge Road, Coleraine BT52 1BS, Northern Ireland
Correspondence to c.magee@armstrongmedical.net

Key words: anaesthesia, carbon dioxide absorption, carbon monoxide, adsorption, sevoflurane, desflurane, isoflurane

Short Summary

AMSORB PLUS and LoFloSorb carbon dioxide (CO₂) absorbents for anaesthesia varied in respect to carbon monoxide (CO) production, anaesthetic agent adsorption and CO₂ absorption capacity in an anaesthesia simulation model. Fresh, partially-desiccated and fresh-desiccated LoFloSorb produced small amounts of CO but markedly adsorbed or eliminated anaesthetic vapour in the order isoflurane → sevoflurane → desflurane with significant adsorption occurring during simultaneous absorption of CO₂ in the first 20 minutes of simulation. Fresh-desiccated LoFloSorb adsorbed 57% of 4% sevoflurane for 74 minutes and 48% of 4% isoflurane for 62 minutes, whereas fresh-desiccated AMSORB PLUS adsorbed 19% for 24 minutes and 3% for 5 minutes respectively. Fresh LoFloSorb caused a delay in reaching 90% (3.6%) of 4% sevoflurane for 37 minutes and took 38 minutes to reach 90% (1.8%) of 2% isoflurane whereas AMSORB PLUS took 8 minutes and 6 minutes respectively. LoFloSorb appeared to possess greater adsorption capability with desflurane, when partially-desiccated, compared to when fresh-desiccated.

Fresh-desiccated and partially-desiccated LoFloSorb absorbed 45% and 90% less CO₂ respectively than fresh and partially-desiccated AMSORB PLUS. There were also differences in respect to the rate at which both absorbents became desiccated by oxygen, with LoFloSorb only marginally more resistant to desiccation compared to AMSORB PLUS. Suitability of LoFloSorb for inhalational anaesthesia should be evaluated by users in respect of their

requirements for patient safety and CO₂ absorption capacity. Further research should consider what happens to anaesthetic vapour that has become adsorbed and whether potential exists for revapourisation of this vapour at some further point, perhaps triggered by an increase in absorbent temperature caused by the exothermic reaction of absorption of CO₂ and whether such unintentional anaesthetic vapourisation poses risk to patients or creates erroneous patient monitoring data.

Abstract

Desiccated soda lime degrades halogenated anaesthetics to carbon monoxide (CO), formaldehyde, methanol, dimethoxymethane and vinyl ethers of which Compound A production, resulting from interaction with sevoflurane, has been described¹. Some desiccated absorbents may concurrently adsorb anaesthetic vapour, in phenomena first described by Grodin². All commercially available medical CO₂ absorbents use calcium hydroxide lime (Ca(OH)₂) as the neutralising base for carbon dioxide (CO₂) produced during anaesthesia respiration. Absorbents differ in minor ingredients, included as absorption catalysts and hardeners, of which sodium hydroxide (NaOH) is common. These ingredients are known to compromise the proper functioning of the absorbent, under specific conditions and with specific types of absorbent. Water is an essential ingredient, common to all absorbents, and is necessary for efficient CO₂ absorption and, in the case of some absorbents, for avoiding

¹ See general reading list in Appendix A

² Grodin WK et al. Soda lime adsorption of isoflurane and enflurane. *Anesthesiology* 1985; vol. 62(1); pp60-64

adsorption and degradation of anaesthetic vapour. In 2005, APSF (Anesthesia Patient Safety Foundation) published a consensus statement³ advising anaesthesia providers against use of absorbents that significantly degrade anaesthetic vapour.

Absorbent hydration levels are known to affect the extent of vapour degradation, with complete desiccation causing most degradation. Content of NaOH in conventional soda lime is known to additionally affect degradation, as does the halogenated agent used, with most degradation (in respect of CO) in the order desflurane → enflurane → isoflurane → sevoflurane → halothane. Absorbent desiccation is caused by inadvertent gas flow through the absorber canister during periods of non-use or, intentionally by evaporation of water during clinical absorption of CO₂, as part of an exothermic reaction during conversion of Ca(OH)₂ to calcium carbonate (CaCO₃), aided by the associated drying effect of fresh gas flow. Desiccated absorbents, in general, are known to adsorb or *eliminate* halogenated anaesthetics, (to varying degrees in respect of some absorbents), with simultaneous degradation of anaesthetic vapour. Absorbents containing molecular sieve zeolites and silica are reported as having significant potential in this regard⁴.

Desiccation of fresh (unused) absorbent has been shown to result from inadvertent gas flow but no data exists on the extent of desiccation from CO₂ absorption alone. Neither does data exist on the ability of clinically exhausted and desiccated absorbent to degrade and adsorb halogenated anaesthetics; as previous studies tested the characteristics of fresh-desiccated but not exhausted absorbents. The role of the insoluble precipitate CaCO₃, a by-product of exhaustion of the absorbent, is of particular interest to the study design with respect to anaesthetic vapour adsorption and degradation. Current advice from manufacturers of some absorbents is that avoiding inadvertent desiccation by gas flow during periods of non-use will render the absorbent otherwise safe to use. This advice may be somewhat misguided, as data has not previously been available to confirm the level of desiccation from clinical exhaustion of the absorbent.

New generation non-soda lime absorbents (NSL), AMSORB® PLUS (Armstrong Medical Limited, Coleraine, Northern Ireland) and LoFloSorb (Intersurgical Limited,

Wokingham, UK) claim to eliminate or reduce, respectively, degradation of vapourous anaesthetics, purportedly making them safer for use than absorbents containing NaOH or other strong alkali base.

The present study examines NSL absorbents' ability to produce CO and adsorb *anaesthetic vapour, in their fresh state, partially-desiccated/exhausted state (hereinafter referred to as partially-desiccated state) when in contact with 2% and 4% isoflurane, 4% and 8% sevoflurane and 12% and 16% desflurane and in their fresh-desiccated state.* 'Fresh state' refers to when the absorbent is unused and has adequate moisture content, in line with random samples of fresh absorbent recovered from hospitals; partially-desiccated state refers to used absorbent, exhausted to 50% of its original viable Ca(OH)₂ content and desiccated from absorption of CO₂ to breakthrough of 0.5% FiCO₂ and then further conditioned to bring the moisture content to 3.8% ±0.5 H₂O by flow of oxygen (note that this further conditioning required a reduction in the hydration level with all absorbents); 'fresh-desiccated state' refers to unused absorbent desiccated by gas flow.

Critical elements such as anaesthetic vapour adsorption and CO production are examined, along with CO₂ absorption capacity, rate of dehydration and permanency of colour change relative to absorbent hydration. Medisorb absorbent (GE Healthcare, Helsinki, Finland) is used as the control in tests. Medisorb is a conventional soda lime, widely reported as having significant capability of producing CO when desiccated and in contact with vapourous anaesthetics⁵.



Fig. 1. Fresh AMSORB PLUS (white coloured) and desiccated AMSORB PLUS (violet coloured)

³ Olympio MA et al. Carbon Dioxide Absorbent Desiccation Safety Conference Convened by APSF. APSF Newsletter Summer 2005, vol. 20, No. 2, pp. 25, 27-29

⁴ Knolle E et al. Small Carbon Monoxide Formation in Absorbents Does Not Correlate with Small Carbon Dioxide Absorption. *Anesthesia & Analgesia* 2002; vol. 95; pp650-655

© 2008 Reproduction of this work, other than for personal or general use in connection with reporting its findings, is prohibited without the written permission of the authors

⁵ Keijzer C et al. Carbon monoxide production from desflurane and six types of carbon dioxide absorbents in a patient model. *Acta Anaesthesiologica Scandinavica* 2005; vol. 49; pp. 815-818




Fig. 2. Fresh LoFloSorb (green coloured)

Full Summary

CO production

Test results show that LoFloSorb produces CO *in vitro* when in contact with vaporous anaesthetics, in the order sevoflurane → isoflurane → desflurane for fresh absorbent and in the order isoflurane → sevoflurane → desflurane for fresh-desiccated absorbent (see tables 1-3). Peak CO levels found with fresh LoFloSorb, across all three anaesthetic agents, reached 7ppm±4 with isoflurane at 4% - less with the other agents. Peak CO levels found with fresh-desiccated LoFloSorb across all three anaesthetic agents, were 48ppm±18 with isoflurane. Fresh or fresh-desiccated AMSORB PLUS did not produce CO beyond background interference (1ppm) in a small number of tests. It should be noted that, when desiccated, neither absorbent has the required capability to absorb clinical loadings of CO₂. This data supports the earlier findings of Knolle.

Table 1.

Sevoflurane 8%	Peak CO	Median CO
AMSORB PLUS, fresh	0	0
LoFloSorb, fresh	5	2
Medisorb, fresh	10	6
AMSORB PLUS, fresh desiccated	1	<1
LoFloSorb, fresh desiccated	40	24
Medisorb, fresh desiccated	410	287

Table 2.

Isoflurane 4%	Peak CO	Median CO
AMSORB PLUS, fresh	0	0
LoFloSorb, fresh	7	3
Medisorb, fresh	25	8
AMSORB PLUS, fresh desiccated	0	0
LoFloSorb, fresh desiccated	48	28
Medisorb, fresh desiccated	810	537

Table 3.

Desflurane 16%	Peak CO	Median CO
AMSORB PLUS, fresh	0	0
LoFloSorb, fresh	6	1
Medisorb, fresh	45	23
AMSORB PLUS, fresh desiccated	0	0
LoFloSorb, fresh desiccated	35	17
Medisorb, fresh desiccated	1,010	693

Data for peak CO production from partially-desiccated absorbent did not prove statistically significant and levels stayed below 55ppm or 0.0055% volume.

Adsorption of Anaesthetic Vapour

Adsorption of anaesthetic vapour was pronounced with fresh, fresh-desiccated and partially-desiccated LoFloSorb and less so with fresh and fresh-desiccated and partially-desiccated Medisorb and AMSORB PLUS (see tables 4-6). Time to equilibrium to 90% of the vapouriser setting was consistently greatest with fresh, fresh-desiccated and partially-desiccated LoFloSorb, with all three anaesthetic agents and least with fresh, fresh-desiccated and partially-desiccated AMSORB PLUS. In all absorbents, the time to equilibrium and the percentage adsorption of the vapour varied with agent concentration and hydration level of the absorbent. Adsorption by fresh LoFloSorb appeared greatest with sevoflurane and isoflurane and less with desflurane. The greatest level of adsorption appeared with fresh-desiccated LoFloSorb and isoflurane at 2% and 4% in which 48% of the delivered anaesthetic vapour was eliminated during the first 40 minutes of the study, with equilibrium to 90% of the vapouriser being achieved at 68 minutes and 62 minutes respectively. Comparative data for fresh LoFloSorb was 38 minutes and 21 minutes for 2% and 4% isoflurane, respectively. For partially-desiccated LoFloSorb, equilibrium was not reached until 29 minutes and 48 minutes for 2% and 4% isoflurane, respectively, suggesting that LoFloSorb, in clinical use, has significant capacity to adsorb anaesthetic vapour, whilst simultaneously absorbing CO₂. The lowest level of agent adsorption by a fresh-desiccated absorbent was recorded with AMSORB PLUS in which equilibrium was reached after just 5 minutes at 4% isoflurane and 6 minutes at 2% isoflurane, suggesting that AMSORB PLUS has very limited capability to adsorb anaesthetic vapour.

Table 4.




	Adsorption	
	Total time to equilibrium (min) to 90% of vapouriser setting	Total vapour volume loss to 40 min (%)
Sevoflurane 8%		
AMSORB PLUS, fresh	8	
LoFloSorb, fresh	28	
Medisorb, fresh	14	
AMSORB PLUS, partially-desiccated	23	
LoFloSorb, partially-desiccated	37	
Medisorb, partially-desiccated	31	
AMSORB PLUS, fresh desiccated	22	19
LoFloSorb, fresh desiccated	80	39
Medisorb, fresh desiccated	41	29

Table 5.

	Adsorption	
	Total time to equilibrium (min) to 90% of vapouriser setting	Total vapour volume loss to 40 min (%)
Isoflurane 4%		
AMSORB PLUS, fresh	6	
LoFloSorb, fresh	21	
Medisorb, fresh	20	
AMSORB PLUS, partially-desiccated	5	
LoFloSorb, partially-desiccated	48	
Medisorb, partially-desiccated	31	
AMSORB PLUS, fresh desiccated	5	3
LoFloSorb, fresh desiccated	62	48
Medisorb, fresh desiccated	32	19

Table 6.

	Adsorption	
	Total time to equilibrium (min) to 90% of vapouriser setting	Total vapour volume loss to 40 min (%)
Desflurane 16%		
AMSORB PLUS, fresh	5	
LoFloSorb, fresh	19	
Medisorb, fresh	17	
AMSORB PLUS, partially-desiccated	3	
LoFloSorb, partially-desiccated	43	
Medisorb, partially-desiccated	13	
AMSORB PLUS, fresh desiccated	6	5
LoFloSorb, fresh desiccated	26	23
Medisorb, fresh desiccated	23	15



CO₂ Absorption Capacity

CO₂ absorption capacity in fresh or partially-desiccated absorbent was greatest with AMSORB PLUS and least with LoFloSorb (see tables 7-9). CO₂ absorption capacity was not influenced by choice of anaesthetic agent but was affected by absorbent hydration levels. Fresh AMSORB PLUS, on average, has 45% more absorption capacity than LoFloSorb, presumably due to the absence of any absorption catalyst within the LoFloSorb formulation. Fresh AMSORB PLUS, on average, has 27% more absorption capacity than Medisorb. More striking results were found for partially-desiccated absorbents, where AMSORB PLUS had almost 10 times more absorption capacity than LoFloSorb, when CO₂ absorption resumed. CO₂ absorption activity in fresh-desiccated absorbent was greatest with Medisorb and least with LoFloSorb and AMSORB PLUS. Of the fresh-desiccated absorbents, only Medisorb demonstrated notable CO₂ absorption activity.

Table 7.

Absorbent	Duration (min)	Average total CO ₂ absorption (L/kg)
AMSORB PLUS fresh 14.6% H ₂ O	691	134
Medisorb fresh 15.8% H ₂ O	510	99
LoFloSorb fresh 14.6% H ₂ O	385	74

Table 8.

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)
AMSORB PLUS partially-desiccated 3.8% H ₂ O	505	97
Medisorb partially-desiccated 3.8% H ₂ O	445	85
LoFloSorb partially-desiccated 3.8% H ₂ O	55	10







Table 9.

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)
Medisorb fresh desiccated <1.1% H ₂ O	85	16.0
LoFloSorb fresh desiccated <1.1% H ₂ O	7	1.2
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2



Temperature

Analysis of peak temperature and time to peak temperature confirmed that temperature elevation, beyond the typical observation of peak temperature in the range 36°C to 44°C during absorption of CO₂ with a hydrated absorbent, was statistically significant in fresh-desiccated Medisorb only (peak of 74°C after 90 minutes) and was consistent with simultaneous production of CO. Peak temperatures below 36°C were consistent with zero or minimal CO₂ absorption activity in fresh-desiccated AMSORB PLUS and LoFloSorb. This would support the assertion that attainment of temperatures above 36°C in these absorbents is related to CO₂ absorption activity, for which at least partial absorbent hydration is required, rather than any heat created by breakdown of anaesthetic agent by these absorbents, given that the levels of breakdown to CO with LoFloSorb are less, relative to levels produced by NaOH-containing absorbents.

Methods

AMSORB PLUS and LoFloSorb were tested in their fresh state, partially-desiccated state and fresh-desiccated state, when in contact with varying percentages of isoflurane, sevoflurane and desflurane in a clinical simulation model. Individual 1.0kg ±20g samples of both materials were chosen from batches of absorbent available in a number of European and USA hospitals. Medisorb (GE Healthcare, Helsinki, Finland) was used as the control in tests.

Conditioning of Samples

Samples were tested in their fresh state or conditioned, as appropriate. All tests were completed in triplicate and data averaged. Samples of absorbent in their fresh state were checked for moisture content, viable lime content and bulk density and placed in sealed vessels as 1.0kg ±20g batches, awaiting testing. Material, to create 1.0kg ±20g fresh-desiccated samples, was prepared from fresh absorbent samples with known moisture content and viable lime

content and bulk density and placed on a two decimal place balance (Kern & Sohn GmbH, Balingen, Germany) in a sealed vessel with inlet and outlet ports. The tared weight of the sample was recorded. Medical oxygen (BOC, UK) was passed into the vessel through the inlet port at 8L.min, exiting the outlet port until the balance showed a constant weight loss. Material to create 1.0kg \pm 20g partially-desiccated samples was prepared from fresh absorbent samples with known moisture content and viable lime content and bulk density and placed in the upper compartment of the circle absorber of anaesthesia machine model Narkomed 6B (Dräger Medical AG, Lubeck, Germany) along with an additional 1.0kg of the same brand of fresh absorbent placed in the lower compartment of the same circle absorber. No data was recorded from the material in the lower compartment and this material was discarded after conditioning of the target material in the upper compartment. A Y-piece breathing circuit was connected to the circle absorber and a test lung (Maquet, Tyne-in-Wear, UK) substituted for a patient lung. CO₂ was introduced to the expiratory limb of the Y-piece circuit at 200mL.min \pm 10 using mass flow controller (McMillian Company, Texas, USA). Fresh gas flow was set at 500mL.min \pm 50 oxygen with the anaesthesia ventilator set to deliver a tidal volume of 500mL at a respiratory rate of 12 breaths per minute. Tidal volume and minute volume were calibrated using a Wright Respirometer (Ferraris Medical Limited, Enfield, UK). Inspiratory limb gas composition was measured using a continuous capnographic gas monitor (Datex Instrumentarium, Helsinki, Finland). Testing ceased when CO₂ exceeded 0.5% of gas volume. The target material was placed in a sealed vessel immediately after 5g was removed for analysis of moisture and remaining viable Ca(OH)₂ content. Viable Ca(OH)₂ varied between 30% and 50% of the initial 820g/kg Ca(OH)₂ in the fresh absorbent, so this data was not correlated further. If required, the target material was further desiccated to 3.8% \pm 0.5 H₂O. Care was taken to cause minimal disturbance of the material during transfer to the sealed vessel. A further 5g of material was taken at 48 hours \pm 8 after the end of conditioning to correlate moisture and remaining viable lime data.

Clinical Simulation Testing on Fresh and Conditioned Samples

Fresh and conditioned samples were tested on a clinical simulation rig (see Fig. 3), specifically developed for testing CO₂ absorbents in simulated circle system anaesthesia, comprising a multi-vapouriser rack (1) with 'draw-over' oxygen and/or nitrous oxide fresh gas flow through gas-

specific flowmeters (2). The anaesthetic vapour/fresh gas preparation was delivered into the reservoir of the collapsing bellows of an Ohio 7000 anaesthetic ventilator (4) (Ohio Medical, Wisconsin, USA) connected within a circle to the absorber assembly of anaesthesia machine model Fabius (3) (Dräger Medical, Lubeck, Germany). A 1.5m length adult Universal F breathing circuit (5) (Armstrong Medical Limited, Coleraine, Northern Ireland) connected a patient test lung (6) (Maquet Limited, Tyne-in-Wear, UK) with the Fabius absorber.




Fig. 3. Simulation Model

20ml H₂O was dissolved in 5g calcium chloride (CaCl₂) and added to the test lung and the test lung immersed in a water bath, maintained at 37°C \pm 3, to simulate the process of pulmonary moisture exchange during low fresh gas flow anaesthesia. CO₂ was introduced to the expiratory limb of the Universal F circuit at 200mL.min \pm 10 using the mass flow controller (McMillian Company, Texas, USA). Fresh gas flow was set at 500mL.min \pm 50 oxygen with the anaesthesia ventilator calibrated to deliver a tidal volume of 500mL at a respiratory rate of 12 breaths per minute at ventilation peak pressure of 30cmH₂O \pm 3. Tidal and minute volumes were calibrated using a Wright Respirometer (Ferraris Medical Limited, Enfield, UK). Testing of target samples aimed to establish the following data points through gas composition sampling, temperature profiling and visual characteristics:

Adsorption

1. **Fresh absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
2. **Partially-desiccated absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
3. **Fresh-desiccated absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
4. **Fresh-desiccated absorbent:** Total loss or *adsorption* of anaesthetic agent at the point of equilibrium of agent to 90% of the vapouriser setting

CO Production

5. **Fresh absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from fresh absorbent
6. **Partially-desiccated absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from partially-desiccated absorbent
7. **Fresh-desiccated absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from fresh-desiccated absorbent

CO₂ Absorption Capacity, Rate of Dehydration and Permanency of Colour Change

- 8-10. CO₂ absorption capacity of fresh absorbent, partially-desiccated absorbent and fresh-desiccated absorbent
11. Rate of dehydration
12. Permanency of colour change

Gas sampling ports (see Fig. 4) were included at (a.) the flowmeters – to verify baseline anaesthetic agent concentration; (b.) the bellows – to verify CO₂ baseline concentration; (c.) the expiratory limb – to measure CO₂ values; (d.) the inspiratory limb – to measure CO₂ and anaesthetic agent values; (e.) the inspiratory limb – to measure CO values. Gas composition at ports (a.), (b.), (c.) and (d.) were measured using a continuous

capnograph/agent gas monitor with gas return (Datex Instrumentarium, Helsinki, Finland). Inspiratory CO values at port (e.) were measured at 1, 5, 10, 20 and 40 minutes using an infrared multi-gas detector without gas return (Dräger Safety AG, Lubeck, Germany). Measurements at ports (c.) and (d.) were taken continuously for CO₂ and at 5, 10, 20 and 40 minutes, or at the point of equilibrium for anaesthetic agent values.




Fig. 4. Simulation Model

Additionally, the Fabius absorber was modified to include an access port for temperature probe (f) Tenma 72-2060, (Tenma, Inc., Ohio, USA) located at circa one third of the height of the absorber unit⁶. Location of the probe tip ensured that temperature readings were taken at 50% of the diameter of the absorber, in order to capture the temperature at the site of absorption and other chemical reactions.

For control, the simulation model was tested using agents isoflurane 2%, sevoflurane 4% and desflurane 12%, without absorbent in the canister, in order to measure any loss of anaesthetic agent or CO₂ or extraneous chemical reaction which might contribute erroneous data when absorbent is used in the model.

Rate of Dehydration

As further control and to add efficacy to the data, experiments were undertaken to assess the absorbents' ability to resist desiccation when in contact with gas flow. The manufacturer of LoFloSorb claims⁷ that the addition, to their formulation, of molecular sieve zeolites and silica enables the absorbent to retain moisture to a greater extent than other absorbents, presumably supporting their claims that it does not become desiccated during use and therefore

⁶ The Fabius absorber requires expiratory gas flow, through the absorber, to be in the direction bottom-to-top

⁷ Intersurgical marketing material

does not possess the ability to degrade the anaesthetic vapour through destruction of or through adsorption of the vapour, as conversely reported by Knolle. 15g±0.2 samples of fresh absorbents, LoFloSorb and AMSORB PLUS were desiccated or further hydrated to a 14% ±0.3 H₂O w/w, as appropriate. These samples were conditioned in triplicate and weighed after being placed in sealed glass u-tubes with glass wool to retain the sample. After 72 hours, the contents of one u-tube of each type of absorbent sample was moisture-tested to verify the conditioned moisture content of 14% ±0.3 H₂O w/w.

The remaining sample pairs were then placed individually on a four decimal place balance (Adam Equipment, Milton Keynes, UK, model ACB) and weighed to determine the gross weight of the U-tube, sample material and rubber bungs and the net weight of absorbent sample. A gas line carrying 1L.min oxygen was connected to the inlet port of the u-tube at room temperature 20°C ±0.5. The time taken to reach a steady weight (for more than 15 minutes) on the balance was recorded to determine total gravimetric weight loss of water from the sample. An identical experiment was conducted on the second of the two remaining pairs and average data, across the pairs, was recorded for final analysis. The contents of the u-tube were then moisture-analysed to verify remaining moisture content.

Permanency of Colour Change

Three sets of 100g samples of fresh AMSORB PLUS and LoFloSorb, which had been used in the simulation rig for CO₂ absorption studies, were further desiccated or hydrated to 6% H₂O to ensure an even colour change to violet, across the entire 100g sample. 6% H₂O was taken as the approximate hydration point where both absorbents changed from their fresh colour to violet, during CO₂ absorption studies on the simulation rig. This moisture content was verified using 10g of spare material produced in excess of the 100g sample. The 100g samples were immediately placed in a sealed vessel and inspected 48 hours later for deterioration of the colour.

Results

Data points 1-12 reported in tables 10-21

Adsorption

1. **Fresh absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
2. **Partially-desiccated absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
3. **Fresh-desiccated absorbent:** Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting
4. **Fresh-desiccated absorbent:** Total loss or *adsorption* of anaesthetic agent at the point of equilibrium of agent to 90% of the vapouriser setting

CO Production

5. **Fresh absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from fresh absorbent
6. **Partially-desiccated absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from partially-desiccated absorbent
7. **Fresh-desiccated absorbent:** CO production at 1, 5, 10, 20 and 40 minutes from fresh-desiccated absorbent

CO₂ Absorption Capacity, Rate of Dehydration and Permanency of Colour Change

- 8-10. CO₂ absorption capacity of fresh absorbent, partially-desiccated absorbent and fresh-desiccated absorbent
11. Rate of dehydration
12. Permanency of colour change

Table 10. Fresh absorbent: Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent	Time to equilibrium w/o absorbent (min)	Agent vapouriser setting (%)	agent vapouriser (%)	agent volume (mL.min)	agent % Fi at 5 min	agent % Fi at 10 min	agent % Fi at 20 min	agent % Fi at 40 min	Total time to equilibrium (min) to 90% of vapouriser setting
Control - no absorbent in use (isoflurane)	0	0	isoflurane (I)	<1	2.0%	2.0	10	2.00	2.00	2.00	2.00	1
Control - no absorbent in use (sevoflurane)	0	0	Sevoflurane (S)	<1	4.0%	4.0	20	4.00	4.00	4.00	4.00	1
Control - no absorbent in use (desflurane)	0	0	Desflurane (D)	<1	12.0%	12.0	60	12.00	12.00	12.00	12.00	1
AMSORB PLUS fresh 14.5% H ₂ O	660	132	Sevoflurane (S)	-	4.0%	4.0	20	2.90	3.60	3.70	3.90	8
LoFloSorb fresh 14.18% H ₂ O	378	75.6	Sevoflurane (S)	-	4.0%	4.0	20	2.60	3.00	3.10	3.70	37
Medisorb fresh 15.9% H ₂ O	505	101	Sevoflurane (S)	-	4.0%	4.0	20	2.60	3.30	3.40	3.90	13
AMSORB PLUS fresh 14.9% H ₂ O	681	136.2	Sevoflurane (S)	-	8.0%	8.0	40	5.90	7.20	7.70	7.90	8
LoFloSorb fresh 14.3% H ₂ O	360	72	Sevoflurane (S)	-	8.0%	8.0	40	4.20	5.10	5.50	7.90	28
Medisorb fresh 15.4% H ₂ O	510	102	Sevoflurane (S)	-	8.0%	8.0	40	4.50	5.90	7.50	7.95	14
AMSORB PLUS fresh 14.9% H ₂ O	682	136.4	isoflurane (I)	-	2.0%	2.0	10	1.60	1.80	1.80	1.90	6
LoFloSorb fresh 14.6% H ₂ O	365	77	isoflurane (I)	-	2.0%	2.0	10	1.10	1.05	1.40	1.88	38
Medisorb fresh 15.8% H ₂ O	480	96	isoflurane (I)	-	2.0%	2.0	10	1.00	1.70	1.90	1.92	19
AMSORB PLUS fresh 14.5% H ₂ O	660	132	isoflurane (I)	-	4.0%	4.0	20	3.10	3.60	3.80	3.95	6
LoFloSorb fresh 14.20% H ₂ O	381	76.2	isoflurane (I)	-	4.0%	4.0	20	2.20	2.90	3.30	3.70	21
Medisorb fresh 16.1% H ₂ O	492	98.4	isoflurane (I)	-	4.0%	4.0	20	2.80	3.50	3.60	3.90	20
AMSORB PLUS fresh 14.6% H ₂ O	691	138.2	Desflurane (D)	-	12.0%	12.0	60	9.50	10.80	11.30	11.80	7
LoFloSorb fresh 14.23% H ₂ O	365	73	Desflurane (D)	-	12.0%	12.0	60	8.80	10.10	10.80	11.20	23
Medisorb fresh 15.8% H ₂ O	510	102	Desflurane (D)	-	12.0%	12.0	60	8.95	9.90	11.10	11.60	15
AMSORB PLUS fresh 14.6% H ₂ O	651	130.2	Desflurane (D)	-	16.0%	16.0	80	12.10	14.40	15.40	15.80	5
LoFloSorb fresh 14.21% H ₂ O	370	74	Desflurane (D)	-	16.0%	16.0	80	10.90	12.10	14.40	15.40	19
Medisorb fresh 15.9% H ₂ O	480	96	Desflurane (D)	-	16.0%	16.0	80	11.05	13.90	14.80	15.80	17

Table 11. Partially-desiccated absorbent: Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent	Time to equilibrium w/o absorbent (min)	Agent vapouriser setting (%)	agent vapouriser (%)	agent volume (mL.min)	agent % Fi at 5 min	agent % Fi at 10 min	agent % Fi at 20 min	agent % Fi at 40 min	Total time to equilibrium (min) to 90% of vapouriser setting
Control - no absorbent in use (isoflurane)	0	0	isoflurane (I)	<1	2.0%	2.0	10	2.00	2.00	2.00	2.00	1
Control - no absorbent in use (sevoflurane)	0	0	Sevoflurane (S)	<1	4.0%	4.0	20	4.00	4.00	4.00	4.00	1
Control - no absorbent in use (desflurane)	0	0	Desflurane (D)	<1	12.0%	12.0	60	12.00	12.00	12.00	12.00	1
AMSORB PLUS partially-desiccated 3.8% H ₂ O	475	95	Sevoflurane (S)	-	4.0%	4.0	20	2.50	3.20	3.50	3.85	21
LoFloSorb partially-desiccated 3.8% H ₂ O	54	10.8	Sevoflurane (S)	-	4.0%	4.0	20	1.80	2.40	3.10	3.80	25
Medisorb partially-desiccated 3.8% H ₂ O	420	84	Sevoflurane (S)	-	4.0%	4.0	20	2.20	3.00	3.50	3.80	21
AMSORB PLUS partially-desiccated 3.8% H ₂ O	501	100.2	Sevoflurane (S)	-	8.0%	8.0	40	3.70	5.10	6.50	7.85	23
LoFloSorb partially-desiccated 3.8% H ₂ O	48	9.6	Sevoflurane (S)	-	8.0%	8.0	40	2.05	2.80	4.50	7.30	37
Medisorb partially-desiccated 3.8% H ₂ O	415	83	Sevoflurane (S)	-	8.0%	8.0	40	3.10	3.90	5.20	7.70	31
AMSORB PLUS partially-desiccated 3.8% H ₂ O	468	93.6	isoflurane (I)	-	2.0%	2.0	10	1.60	1.80	1.90	2.00	2
LoFloSorb partially-desiccated 3.8% H ₂ O	55	11	isoflurane (I)	-	2.0%	2.0	10	0.30	0.89	0.98	1.80	29
Medisorb partially-desiccated 3.8% H ₂ O	430	86	isoflurane (I)	-	2.0%	2.0	10	0.90	1.25	1.60	1.90	19
AMSORB PLUS partially-desiccated 3.8% H ₂ O	440	88	isoflurane (I)	-	4.0%	4.0	20	3.60	3.60	3.80	3.85	5
LoFloSorb partially-desiccated 3.8% H ₂ O	43	8.6	isoflurane (I)	-	4.0%	4.0	20	0.55	0.90	1.90	3.40	48
Medisorb partially-desiccated 3.8% H ₂ O	390	78	isoflurane (I)	-	4.0%	4.0	20	1.70	2.50	3.20	3.80	31
AMSORB PLUS partially-desiccated 3.8% H ₂ O	505	101	Desflurane (D)	-	12.0%	12.0	60	11.65	11.90	11.90	11.90	3
LoFloSorb partially-desiccated 3.8% H ₂ O	61	12.2	Desflurane (D)	-	12.0%	12.0	60	4.10	8.90	10.20	11.40	22
Medisorb partially-desiccated 3.8% H ₂ O	445	89	Desflurane (D)	-	12.0%	12.0	60	7.70	10.10	11.20	11.80	16
AMSORB PLUS partially-desiccated 3.8% H ₂ O	482	96.4	Desflurane (D)	-	16.0%	16.0	80	14.75	15.50	15.70	15.70	3
LoFloSorb partially-desiccated 3.8% H ₂ O	50	10	Desflurane (D)	-	16.0%	16.0	80	6.40	7.90	11.50	14.10	43
Medisorb partially-desiccated 3.8% H ₂ O	412	82.4	Desflurane (D)	-	16.0%	16.0	80	6.75	13.30	14.80	15.50	13

Table 12. Fresh-desiccated absorbent: Inspiratory anaesthetic agent concentration, relative to vapouriser setting at 5, 10, 20 and 40 minutes and at the point of equilibrium of agent to 90% of the vapouriser setting

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent	Time to equilibrium who absorbent (min)	Agent vapouriser setting (%)	agent vapouriser (%)	agent volume (mL min)	agent % Fi at 5 min	agent % Fi at 10 min	agent % Fi at 20 min	agent % Fi at 40 min	Total time to equilibrium (min) to 90% of vapouriser setting
Control - no absorbent in use (isoflurane)	0	0	isoflurane (I)	<1	2.0%	2.0	10	2.00	2.00	2.00	2.00	1
Control - no absorbent in use (sevoflurane)	0	0	Sevoflurane (S)	<1	4.0%	4.0	20	4.00	4.00	4.00	4.00	1
Control - no absorbent in use (desflurane)	0	0	Desflurane (D)	<1	12.0%	12.0	60	12.00	12.00	12.00	12.00	1
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2	Sevoflurane (S)	-	4.0%	4.0	20	1.10	1.80	3.40	3.90	24
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Sevoflurane (S)	-	4.0%	4.0	20	0.60	0.90	1.10	1.80	74
Medisorb fresh desiccated <1.1% H ₂ O	80	16	Sevoflurane (S)	-	4.0%	4.0	20	0.71	1.20	2.00	3.90	37
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	>0.2	Sevoflurane (S)	-	8.0%	8.0	40	3.10	4.30	5.70	7.70	22
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Sevoflurane (S)	-	8.0%	8.0	40	0.36	1.60	4.50	6.10	80
Medisorb fresh desiccated <1.1% H ₂ O	72	14.4	Sevoflurane (S)	-	8.0%	8.0	40	1.10	3.20	3.80	7.30	41
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2	isoflurane (I)	-	2.0%	2.0	10	1.60	1.80	1.90	2.00	6
LoFloSorb fresh desiccated <1.1% H ₂ O	5	1	isoflurane (I)	-	2.0%	2.0	10	0.15	0.30	0.69	1.30	68
Medisorb fresh desiccated <1.1% H ₂ O	85	17	isoflurane (I)	-	2.0%	2.0	10	0.23	0.60	1.20	1.80	40
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	>0.2	isoflurane (I)	-	4.0%	4.0	20	3.60	3.80	3.95	3.95	5
LoFloSorb fresh desiccated <1.1% H ₂ O	7	1.4	isoflurane (I)	-	4.0%	4.0	20	0.70	1.10	1.90	2.20	62
Medisorb fresh desiccated <1.1% H ₂ O	71	14.2	isoflurane (I)	-	4.0%	4.0	20	1.20	2.50	3.10	3.80	32
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	>0.2	Desflurane (D)	-	12.0%	12.0	60	9.20	10.80	11.30	11.60	9
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Desflurane (D)	-	12.0%	12.0	60	2.10	4.50	8.90	10.80	28
Medisorb fresh desiccated <1.1% H ₂ O	80	16	Desflurane (D)	-	12.0%	12.0	60	6.10	8.80	9.50	11.60	22
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2	Desflurane (D)	-	16.0%	16.0	80	11.80	14.80	15.60	15.70	6
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Desflurane (D)	-	16.0%	16.0	80	4.10	7.20	12.10	14.90	26
Medisorb fresh desiccated <1.1% H ₂ O	68	13.6	Desflurane (D)	-	16.0%	16.0	80	7.20	9.40	13.60	15.60	23

Table 13. Fresh-desiccated absorbent: Total loss or adsorption of anaesthetic agent at the point of equilibrium of agent to 90% of the vapouriser setting

Absorbent	Agent	agent vapouriser (%)	agent volume (mL min)	agent % Fi at 5 min	agent % Fi at 10 min	agent % Fi at 20 min	agent % Fi at 40 min	total time to equilibrium (min) to 90% of vapouriser setting	agent molecular mass per mol (g)	agent density (g/cc)	Cumulative agent vapour loss to 40 min (mL)	Total vapour volume inflow to 40 min	Total vapour volume loss to 40 min (%)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	20	1.10	1.80	3.40	3.90	24	20.0	152	153	800.0	19%
LoFloSorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	20	0.60	0.90	1.10	1.80	74	20.0	152	455	800.0	57%
Medisorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	20	0.71	1.20	2.00	3.90	37	20.0	152	212	800.0	27%
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	40	3.10	4.30	5.70	7.70	22	20.0	152	303	1600.0	19%
LoFloSorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	40	0.36	1.60	4.50	6.10	80	20.0	152	629	1600.0	39%
Medisorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	40	1.10	3.20	3.80	7.30	41	20.0	152	468	1600.0	29%
AMSORB PLUS fresh desiccated <1.1% H ₂ O	isoflurane (I)	2.0%	10	1.60	1.80	1.90	2.00	6	184.5	145	18	400.0	4%
LoFloSorb fresh desiccated <1.1% H ₂ O	isoflurane (I)	2.0%	10	0.15	0.30	0.69	1.30	68	184.5	145	192	400.0	48%
Medisorb fresh desiccated <1.1% H ₂ O	isoflurane (I)	2.0%	10	0.23	0.60	1.20	1.80	40	184.5	145	119	400.0	30%
AMSORB PLUS fresh desiccated <1.1% H ₂ O	isoflurane (I)	4.0%	20	3.60	3.80	3.95	3.95	5	184.5	145	21	800.0	3%
LoFloSorb fresh desiccated <1.1% H ₂ O	isoflurane (I)	4.0%	20	0.70	1.10	1.90	2.20	62	184.5	145	388	800.0	48%
Medisorb fresh desiccated <1.1% H ₂ O	isoflurane (I)	4.0%	20	1.20	2.50	3.10	3.80	32	184.5	145	150	800.0	19%
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	60	9.20	10.80	11.30	11.60	9	168	140	158	2400.0	7%
LoFloSorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	60	2.10	4.50	8.90	10.80	28	168	140	633	2400.0	26%
Medisorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	60	6.10	8.80	9.50	11.60	22	168	140	330	2400.0	14%
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	80	11.80	14.80	15.60	15.70	6	168	140	175	3200.0	5%
LoFloSorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	80	4.10	7.20	12.10	14.90	26	168	140	725	3200.0	23%
Medisorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	80	7.20	9.40	13.60	15.60	23	168	140	485	3200.0	15%

Table 14. Fresh absorbent: CO production at 1, 5, 10, 20 and 40 minutes

Absorbent	Agent	Agent vapouriser setting (%)	Peak CO (ppm)	Time to peak CO (min)	Median CO (ppm)	CO at 1 min (ppm)	CO at 5 min (ppm)	CO at 10 min (ppm)	CO at 15 min (ppm)	CO at 20 min (ppm)	CO at 40 min (ppm)	Peak temperature (°C)	Time to peak temperature (min)
AMISORB PLUS fresh 14.5% H ₂ O	Sevoflurane (S)	4.0%	0	-	0	0	0	0	0	0	0	37.1	58.0
LoFbSorb fresh 14.18% H ₂ O	Sevoflurane (S)	4.0%	6	9	2	0	5	6	0	0	0	39.0	46.0
Medisob fresh 15.9% H ₂ O	Sevoflurane (S)	4.0%	8	15	4	0	0	5	8	5	5	42.0	60.0
AMISORB PLUS fresh 14.9% H ₂ O	Sevoflurane (S)	8.0%	0	-	0	0	0	0	0	0	0	34.0	34.0
LoFbSorb fresh 14.3% H ₂ O	Sevoflurane (S)	8.0%	5	5	2	0	5	5	0	0	0	41.0	48.0
Medisob fresh 15.4% H ₂ O	Sevoflurane (S)	8.0%	10	16	6	5	5	8	10	5	0	44.0	55.0
AMISORB PLUS fresh 14.9% H ₂ O	Isflurane (I)	2.0%	0	-	0	0	0	0	0	0	0	36.0	31.0
LoFbSorb fresh 14.6% H ₂ O	Isflurane (I)	2.0%	6	14	2	6	5	0	0	0	0	41.0	37.0
Medisob fresh 15.8% H ₂ O	Isflurane (I)	2.0%	20	5	5	2	20	10	0	0	0	43.0	>80
AMISORB PLUS fresh 14.5% H ₂ O	Isflurane (I)	4.0%	0	-	0	0	0	0	0	0	0	40.0	>60
LoFbSorb fresh 14.20% H ₂ O	Isflurane (I)	4.0%	7	7	3	5	5	5	0	0	0	41.0	>60
Medisob fresh 16.1% H ₂ O	Isflurane (I)	4.0%	25	8	8	5	10	20	10	0	0	42.0	54.0
AMISORB PLUS fresh 14.6% H ₂ O	Desflurane (D)	12.0%	0	-	0	0	0	0	0	0	0	39.0	43.0
LoFbSorb fresh 14.23% H ₂ O	Desflurane (D)	12.0%	5	8	2	0	5	7	0	0	0	37.4	27.0
Medisob fresh 15.8% H ₂ O	Desflurane (D)	12.0%	35	12	20	10	20	25	30	20	15	45.0	>60
AMISORB PLUS fresh 14.6% H ₂ O	Desflurane (D)	16.0%	0	-	0	0	0	0	0	0	0	38.0	33.0
LoFbSorb fresh 14.21% H ₂ O	Desflurane (D)	16.0%	6	5	1	0	5	0	0	0	0	35.0	21.0
Medisob fresh 15.9% H ₂ O	Desflurane (D)	16.0%	45	10	23	15	20	45	20	20	15	42.0	>60

Table 15. Partially-desiccated absorbent: CO production at 1, 5, 10, 20 and 40 minutes

Absorbent	Agent	Agent vapouriser setting (%)	Peak CO (ppm)	Time to peak CO (min)	Median CO (ppm)	CO at 1 min (ppm)	CO at 5 min (ppm)	CO at 10 min (ppm)	CO at 15 min (ppm)	CO at 20 min (ppm)	CO at 40 min (ppm)	Peak temperature (°C)	Time to peak temperature (min)
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	4.0%	0	-	0	0	0	0	0	0	0	36.0	44.0
LoFbSorb partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	4.0%	4	5	1	0	4	0	0	0	0	35.0	50.0
Medisob partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	4.0%	10	15	3	0	0	5	10	5	0	44.0	65.0
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	8.0%	0	-	0	0	0	0	0	0	0	38.0	35.0
LoFbSorb partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	8.0%	7	5	1	0	7	0	0	0	0	42.0	49.0
Medisob partially-desiccated 3.8% H ₂ O	Sevoflurane (S)	8.0%	10	16	6	5	5	8	10	5	0	44.0	59.0
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Isflurane (I)	2.0%	0	-	0	0	0	0	0	0	0	37.0	30.0
LoFbSorb partially-desiccated 3.8% H ₂ O	Isflurane (I)	2.0%	3	9	0	0	2	0	0	0	0	43.0	57.0
Medisob partially-desiccated 3.8% H ₂ O	Isflurane (I)	2.0%	22	5	6	2	22	10	0	0	0	43.0	78.0
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Isflurane (I)	4.0%	0	-	0	0	0	0	0	0	0	39.0	>80
LoFbSorb partially-desiccated 3.8% H ₂ O	Isflurane (I)	4.0%	4	5	1	0	4	0	0	0	0	40.0	>60
Medisob partially-desiccated 3.8% H ₂ O	Isflurane (I)	4.0%	20	8	8	5	10	20	10	0	0	43.0	>60
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Desflurane (D)	12.0%	0	-	0	0	0	0	0	0	0	38.0	44.0
LoFbSorb partially-desiccated 3.8% H ₂ O	Desflurane (D)	12.0%	5	5	1	0	5	0	0	0	0	36.0	31.0
Medisob partially-desiccated 3.8% H ₂ O	Desflurane (D)	12.0%	35	12	20	10	20	25	30	20	15	46.0	>60
AMISORB PLUS partially-desiccated 3.8% H ₂ O	Desflurane (D)	16.0%	0	-	0	0	0	0	0	0	0	38.0	38.0
LoFbSorb partially-desiccated 3.8% H ₂ O	Desflurane (D)	16.0%	6	5	1	0	5	0	0	0	0	38.0	28.0
Medisob partially-desiccated 3.8% H ₂ O	Desflurane (D)	16.0%	55	10	27	15	30	55	25	20	15	45.0	>60

Table 16. Fresh-desiccated absorbent: CO production at 1, 5, 10, 20 and 40 minutes

Absorbent	Agent	Agent vapouriser setting (%)	Peak CO (ppm)	Time to peak CO (min)	Median CO (ppm)	CO at 1 min (ppm)		CO at 5 min (ppm)		CO at 10 min (ppm)		CO at 15 min (ppm)		CO at 20 min (ppm)		Peak temperature (°C)	Time to peak temperature (min)
						min	min	min	min	min	min	min	min	min	min		
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	0	-	0	0	0	0	0	0	0	0	0	0	38.0	39.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	35	12	23	7	15	35	30	30	20	30	20	30	37.0	20.0	
Medisorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	4.0%	350	38	237	70	180	220	280	280	320	350	320	350	52.0	36.0	
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	1	2	0	1	0	0	0	0	0	0	0	0	24.0	34.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	40	10	24	10	20	40	30	30	24	20	24	20	54.0	27.0	
Medisorb fresh desiccated <1.1% H ₂ O	Sevoflurane (S)	8.0%	410	24	287	100	210	290	350	350	410	360	410	360	31.0	31.0	
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Isflurane (I)	2.0%	0	-	0	0	0	0	0	0	0	0	0	0	36.0	22.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Isflurane (I)	2.0%	18	10	10	10	18	10	10	10	5	5	5	5	38.0	18.0	
Medisorb fresh desiccated <1.1% H ₂ O	Isflurane (I)	2.0%	675	15	443	110	200	450	675	620	605	605	605	605	72.2	36.0	
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Isflurane (I)	4.0%	0	-	0	0	0	0	0	0	0	0	0	0	37.0	25.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Isflurane (I)	4.0%	48	8	28	15	30	45	35	35	20	20	20	20	41.0	22.0	
Medisorb fresh desiccated <1.1% H ₂ O	Isflurane (I)	4.0%	810	18	537	130	325	505	720	790	750	750	750	750	74.0	31.0	
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	0	-	0	0	0	0	0	0	0	0	0	0	36.7	20.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	30	12	22	5	20	25	30	30	30	20	20	20	38.5	23.0	
Medisorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	12.0%	905	15	608	145	360	560	905	860	810	810	810	810	73.0	35.0	
AMSORB PLUS fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	0	-	0	0	0	0	0	0	0	0	0	0	38.3	18.0	
LoFloSorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	35	9	17	5	11	33	20	20	20	15	15	15	36.7	20.0	
Medisorb fresh desiccated <1.1% H ₂ O	Desflurane (D)	16.0%	1010	12	693	160	405	945	980	860	860	820	820	820	71.0	35.0	

Table 17. CO₂ absorption capacity of 1.0kg fresh absorbent to 0.5%Fi CO₂ using 200mL.min CO₂ in 500mL.min oxygen at Tv 500mL/12RR

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent
AMSORB PLUS fresh 14.6% H ₂ O	691	138	Desflurane (D)
AMSORB PLUS fresh 14.9% H ₂ O	682	136	Isoflurane (I)
AMSORB PLUS fresh 14.9% H ₂ O	681	136	Sevoflurane (S)
AMSORB PLUS fresh 14.5% H ₂ O	660	132	Isoflurane (I)
AMSORB PLUS fresh 14.6% H ₂ O	651	130	Desflurane (D)
Medisorb fresh 15.8% H ₂ O	510	102	Desflurane (D)
Medisorb fresh 15.4% H ₂ O	510	102	Sevoflurane (S)
Medisorb fresh 16.1% H ₂ O	492	98	Isoflurane (I)
Medisorb fresh 15.9% H ₂ O	480	96	Desflurane (D)
Medisorb fresh 15.8% H ₂ O	480	96	Isoflurane (I)
LoFloSorb fresh 14.6% H ₂ O	385	77	Isoflurane (I)
LoFloSorb fresh 14.20% H ₂ O	381	76	Isoflurane (I)
LoFloSorb fresh 14.21% H ₂ O	370	74	Desflurane (D)
LoFloSorb fresh 14.23% H ₂ O	365	73	Desflurane (D)
LoFloSorb fresh 14.3% H ₂ O	360	72	Sevoflurane (S)

Table 18. CO₂ absorption capacity of 1.0kg partially-desiccated absorbent to 0.5%Fi CO₂ using 200mL.min CO₂ in 500mL.min oxygen at Tv 500mL/12RR

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent
AMSORB PLUS partially-desiccated 3.8% H ₂ O	505	101	Desflurane (D)
AMSORB PLUS partially-desiccated 3.8% H ₂ O	501	100	Sevoflurane (S)
AMSORB PLUS partially-desiccated 3.8% H ₂ O	482	96	Desflurane (D)
AMSORB PLUS partially-desiccated 3.8% H ₂ O	475	95	Sevoflurane (S)
AMSORB PLUS partially-desiccated 3.8% H ₂ O	468	94	Isoflurane (I)
Medisorb partially-desiccated 3.8% H ₂ O	445	89	Desflurane (D)
Medisorb partially-desiccated 3.8% H ₂ O	430	86	Isoflurane (I)
Medisorb partially-desiccated 3.8% H ₂ O	420	84	Sevoflurane (S)
Medisorb partially-desiccated 3.8% H ₂ O	415	83	Sevoflurane (S)
Medisorb partially-desiccated 3.8% H ₂ O	412	82	Desflurane (D)
LoFloSorb partially-desiccated 3.8% H ₂ O	55	11	Isoflurane (I)
LoFloSorb partially-desiccated 3.8% H ₂ O	54	11	Sevoflurane (S)
LoFloSorb partially-desiccated 3.8% H ₂ O	50	10	Desflurane (D)
LoFloSorb partially-desiccated 3.8% H ₂ O	48	10	Sevoflurane (S)
LoFloSorb partially-desiccated 3.8% H ₂ O	43	9	Isoflurane (I)

Table 19. CO₂ absorption capacity of 1.0kg fresh-desiccated absorbent to 0.5%Fi CO₂ using 200mL.min CO₂ in 500mL.min oxygen at Tv 500mL/12RR

Absorbent	Duration (min)	Total CO ₂ absorption (L/kg)	Agent
Medisorb fresh desiccated <1.1% H ₂ O	85	17.0	Desflurane (D)
Medisorb fresh desiccated <1.1% H ₂ O	80	16.0	Sevoflurane (S)
Medisorb fresh desiccated <1.1% H ₂ O	80	16.0	Desflurane (D)
Medisorb fresh desiccated <1.1% H ₂ O	72	14.4	Sevoflurane (S)
LoFloSorb fresh desiccated <1.1% H ₂ O	7	1.4	Isoflurane (I)
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Sevoflurane (S)
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Sevoflurane (S)
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Desflurane (D)
LoFloSorb fresh desiccated <1.1% H ₂ O	6	1.2	Isoflurane (I)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2	Desflurane (D)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	0.2	Sevoflurane (S)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	1	0.2	Isoflurane (I)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	0.2	Isoflurane (I)
AMSORB PLUS fresh desiccated <1.1% H ₂ O	<1	0.2	Sevoflurane (S)

Rate of Dehydration

(11) Both AMSORB PLUS conditioned samples had 2.15g H₂O at the start of the dehydration test. 94.74% of the water was removed by dehydration within 6-hours. A constant weight was reached at 11-hours when 97.53% H₂O was removed to leave moisture content of 0.4%. Both LoFloSorb conditioned samples had 2.083g H₂O at the start of the dehydration test. 86.89% of the water was removed by dehydration within 6-hours. A constant weight was reached at 14 hours when 93.37% H₂O was removed to leave moisture content of 0.95%.

If this data were scaled to 1.0kg fresh absorbent, AMSORB PLUS would desiccate to 0.40% H₂O w/w after 733-hours exposed to 1.0L.min oxygen or 92-hours at 8.0L.min. LoFloSorb would desiccate to 0.95% H₂O w/w after 932-hours exposed to 1.0L.min oxygen or 117-hours at 8.0L.min.

Table 20. Loss of water from fresh AMSORB PLUS at 14% H₂O w/w

AMSORB PLUS		
Time (hours)	Mass Loss (g)	Water loss (%)
0	0.000	0.00
0.5	0.405	18.85
1	0.775	36.08
1.5	1.095	50.98
2	1.420	66.11
2.5	1.580	73.56
3	1.700	79.14
3.5	1.785	83.10
4	1.895	88.22
5	2.010	93.58
6	2.035	94.74
7	2.060	95.90
8	2.070	96.37
9	2.083	96.97
10	2.090	97.30
11	2.095	97.53




Table 21. Loss of water from fresh LoFloSorb at 14% H₂O w/w

LoFloSorb		
Time (hours)	Mass Loss (g)	Water loss (%)
0	0.000	0.00
0.5	0.430	20.64
1	0.755	36.25
1.5	1.020	48.97
2	1.255	60.25
2.5	1.430	68.65
3	1.580	75.85
3.5	1.675	80.41
4	1.730	83.05
5	1.770	84.97
6	1.810	86.89
7	1.830	87.85
9	1.860	89.29
11	1.910	91.69
14	1.945	93.37




Fig. 5. 15g LoFloSorb desiccated by oxygen



Fig. 6. 15g AMSORB PLUS desiccated by oxygen

Permanency of Colour Change

(12) The violet colour of all three LoFloSorb samples had receded to a consistent grey-green colour, closer to its fresh colour (green) than to its indicating colour (violet). The colour of all AMSORB PLUS samples remained violet at 48-hours and 72-hours.



Fig. 7. Exhausted LoFloSorb after 48 hours in a sealed vessel



Fig. 8. Exhausted AMSORB PLUS after 48 hours in a sealed vessel

Discussion

AMSORB PLUS is widely reported as a safe alternative to the use of soda limes or NaOH-containing absorbents during inhalational anaesthesia due to its inability to degrade anaesthetic vapour. AMSORB PLUS does not contain strong base alkali components, such as those in conventional soda lime absorbent formulations. The colour change mechanism of AMSORB PLUS appears to be an incidental benefit to its use, by providing an accurate indication of hydrated state and, hence, remaining absorptive

capacity⁸. NaOH-containing absorbents are not capable of colouring or remaining coloured in response to desiccation and are therefore likely to be used inadvertently, as desiccated or partially-desiccated absorbent, on patients. The patient safety risks with use of this type of absorbent are widely known. LoFloSorb is a NSL absorbent, utilising silica and molecular sieve zeolites⁹ within its formulation to aid absorption. Other studies confirm LoFloSorb produces CO and adsorbs anaesthetic vapour when desiccated. Knolle¹⁰ reported a loss or adsorption of 89%±5 of the inflow of 0.5% isoflurane for over 60 minutes from the start of the test. This showed that desiccated LoFloSorb seriously inhibited the delivery of anaesthetic vapour and, in clinical use this could pose a serious risk to patient well-being and comfort. The capability of desiccated LoFloSorb to adsorb anaesthetic agent is therefore significant and is confirmed in this study but the present study additionally demonstrates significant adsorption of vapour when LoFloSorb is fresh or is partially-desiccated, relative to the performance of AMSORB PLUS and Medisorb. This behaviour may be due to the use of silica and zeolites in LoFloSorb, which published clinical papers¹¹ show entrap vapourised drugs as well as CO₂. A common example of this is the use of molecular sieve crystals in the scavenging system of anaesthetic machines, which adsorb waste anaesthetic vapour. The extent to which fresh or partially-desiccated LoFloSorb is capable of adsorbing anaesthetic vapour, whilst simultaneously absorbing CO₂ should be carefully considered before clinical use. Inadequate delivery of anaesthetic vapour to the patient especially in the early stages of anaesthesia may expose the patient to inadequate anaesthesia and surgical pain that may be masked if muscle relaxant drugs are used concomitantly. The present study did not examine what happens to adsorbed anaesthetic vapour. It is possible that such vapour condenses to liquid on the surface of absorbent material and is re-vapourised as absorbent temperature rises due to heat produced from the absorption of CO₂. This secondary vapourisation would add vapour to the intentional delivery of vapour via the vapouriser dial setting causing anomalies between inspired/expired values and those of the vapouriser dial setting. If undetected, patients could receive elevated and/or erratic levels of anaesthetic vapour, potentially resulting in inadvertent changes to blood pressure

⁸ Knolle E *et al.* Amsorb Changes Colour on Drying Because of the Absence of Strong Base. *Anesthesiology* 2002; vol. 96; A-1155. Abstract from ASA 2002, Orlando

⁹ Olympio MA *et al.* Carbon Dioxide Absorbent Desiccation Safety Conference Convened by APSF. *APSF Newsletter* Summer 2005, vol. 20, No. 2, pp. 25, 27-29

¹⁰ Knolle E *et al.* Small Carbon Monoxide Formation in Absorbents Does Not Correlate with Small Carbon Dioxide Absorption. *Anesthesia & Analgesia* 2002; vol. 95; pp650-655

¹¹ Fee JP *et al.* Molecular Sieves: an Alternative Method of Carbon Dioxide Removal does not Generate Compound A during Simulated Low-Flow Sevoflurane Anaesthesia. *Anaesthesia* 1995; vol. Oct 50(10); pp841-845

and cardiac output or trigger post-operative nausea or other complications from anaesthetic over-delivery.

Data from the present study highlights the limited CO₂ absorption capacity of LoFloSorb when fresh or when partially-desiccated, relative to that of AMSORB PLUS and Medisorb under the same conditions, which appears to be further limited as moisture content reduces. The impact of such limited absorption capacity should be carefully considered during low fresh gas flow anaesthesia and lengthy surgical cases. All absorbents lose moisture, to varying extents, during clinical CO₂ absorption, which theoretically reduces absorption capacity. However, the present study suggests a ten-fold decrease in absorption capacity, when LoFloSorb is compared to AMSORB PLUS when both materials reach 3.8% H₂O, suggesting that the relationship between Ca(OH)₂, moisture and other absorbent ingredients, has a significant bearing on absorption capacity in different brands of absorbent.

The rate at which LoFloSorb becomes desiccated, *in vitro*, by oxygen, relative to the desiccation rate of AMSORB PLUS, further adds substance to this argument.

Whilst it is widely accepted that NaOH-containing absorbents pose risk to patients, if used under particular conditions, LoFloSorb, like AMSORB PLUS, is presented as an absorbent to be used where physicians are concerned about adverse reactions between the absorbent and anaesthetic vapour. This study concludes that, given the findings of this study, considered opinion should be given to the use of LoFloSorb in inhalational anaesthesia.

Appendix A

1. **Baum J et al.** Calcium hydroxide lime – a new carbon dioxide absorbent: a rationale for judicious use of different absorbents. *European Jn. of Anaesthesiology* 2000; vol. 17; pp597-600
2. **Bedi A et al.** The *in vitro* performance of carbon dioxide absorbents with and without strong alkali. *Anaesthesia* 2001; vol. 56; pp. 1-6
3. **Bedi et al.** The *In Vitro* Degradation of Sevoflurane to Formaldehyde Following Exposure to CO₂ Absorbents. *Anesthesiology* 2001; vol. 95; A-1190. Abstract from ASA 2001, New Orleans
4. **Coppens et al.** The mechanisms of carbon monoxide production by inhalational agents. *Anaesthesia* 2006; vol. 61; pp. 462-468
5. **D'Eramo CD.** AMSORB[®]: safety and absorptive capacity during low-flow anaesthesia. Preliminary clinical experience. *Università di Parma* 2001
6. **Di Filippo A et al.** Sevoflurane low-flow anaesthesia: best strategy to reduce Compound A concentration. *Acta Anaesthesiologica Scandinavica*, 2002; vol. 46; pp 1017-1020
7. **Ebert TJ et al.** A New Carbon Dioxide Absorbent Devoid of Anesthetic Breakdown. *Anesthesiology* 2000; vol 93; A-90. Abstract from ASA 2000, San Francisco
8. **Keijzer C et al.** Compound A and carbon monoxide production from sevoflurane and seven different types of carbon dioxide absorbent in a patient model. *Acta Anaesthesiologica Scandinavica* 2007; vol 51; pp31-37
9. **Keijzer C et al.** Carbon monoxide production from desflurane and six types of carbon dioxide absorbents in a patient model. *Acta Anaesthesiologica Scandinavica* 2005; vol. 49; pp. 815-818
10. **Kharasch ED et al.** Comparison of Amsorb[®], Sodasorb and Baralyme[®] Degradation of Volatile Anesthetics and Formation of Carbon Monoxide and Compound A in Swine *In Vivo*. *Anesthesiology* 2002; vol. 96 pp173-182
11. **Kharasch ED et al.** Comparison of Amsorb[®], Sodasorb, and Baralyme[®] Degradation of Desflurane and Isoflurane and on Formation of Carbon Monoxide in Swine *In Vivo*. *Anesthesiology* 2001; vol. 95; A-1125. Abstract from ASA 2001, New Orleans
12. **Kharasch ED et al.** Comparison of Amsorb[®], Sodasorb, and Baralyme[®] Degradation of Sevoflurane and on Formation of Compound A in Swine *In Vivo*. *Anesthesiology* 2001; vol. 95; A-1124. Abstract from ASA 2001, New Orleans
13. **Kharasch ED.** Putting the Brakes on Anesthetic Breakdown. *Anesthesiology* 1999; vol. 91; pp1192-1194
14. **Knolle E et al.** The Colour Change in CO₂ Absorbents on Drying: An *In Vitro* Study Using Moisture Analysis. *Anesthesia & Analgesia* 2003; vol. 97; pp151-155
15. **Knolle E et al.** Small Carbon Monoxide Formation in Absorbents Does Not Correlate with Small Carbon Dioxide Absorption. *Anesthesia & Analgesia* 2002; vol. 95; pp650-655
16. **Knolle E et al.** Amsorb Changes Colour on Drying Because of the Absence of Strong Base. *Anesthesiology* 2002; vol. 96; A-1155. Abstract from ASA 2002, Orlando
17. **Knolle E et al.** The Missing Colour Change from Drying in Strong Base-Containing Absorbents is Not Due to the Hygroscopic Properties of NaOH and KOH. *Anesthesiology* 2002; vol. 96; A-1156. Abstract from ASA 2002, Orlando
18. **Knolle E et al.** Using Amsorb to Detect Dehydration of CO₂ Absorbents Containing Strong Base. *Anesthesiology* 2002; vol. 97; no. 2; pp454-459
19. **Knolle E et al.** Carbon Monoxide Formation in Five Soda Lime Brands with Different Content of Alkali Hydroxides. *Anesthesiology* 2000; vol 93; A-1236. Abstract from ASA 2000, San Francisco
20. **Kobayashi S et al.** Compound A Concentration in the Circle Absorber System during Low Flow Sevoflurane Anesthesia Comparison between Dräger sorb Free[®], Amsorb[®] and Sodasorb II[®] J. Clin. Anesth., Vol. 15, Feb. 2003
21. **Murray JM et al.** Amsorb - A New Carbon Dioxide Absorbent for Use in Anesthetic Breathing Systems. *Anesthesiology* 1999; vol. 91; pp1342-1348
22. **Olympio MA et al.** Carbon Dioxide Absorbent Desiccation Safety Conference Convened by APSF. *APSF Newsletter Summer 2005*, vol. 20, No. 2, pp. 25, 27-29
23. **Olympio MA et al.** Canister Fires Become A Hot Safety Concern. *APSF Newsletter 2004*. Winter.
24. **Renfrew C et al.** A New Approach to Carbon Dioxide Absorbents. *ACTA Anaesthesiologica Scandinavica* 1998; vol. 42; pp58-55
25. **Stabernack CR et al.** Absorbents Differ Enormously in Their Capacity to Produce Compound A and Carbon Monoxide. *Anesthesia & Analgesia* 2000; vol. 90; pp1428-1435
26. **Struys MMRF et al.** Production of compound A and carbon monoxide in circle systems: an *in vitro* comparison of two carbon dioxide absorbents. *Anaesthesia* 2004; vol. 59; pp584-589
27. **Versichelen LFM et al.** Only Carbon Dioxide Absorbents Free of Both NaOH and KOH Do Not Generate Compound A during *In Vitro* Closed-system Sevoflurane. *Anesthesiology* 2001; vol. 95; pp750-755
28. **Bedi et al.** The *In Vitro* Degradation of Sevoflurane to Formaldehyde Following Exposure to CO₂ Absorbents. *Anesthesiology* 2001; vol. 95; A1190. Abstract from ASA 2001, New Orleans.
29. **Bedi et al.** Postoperative nausea and vomiting following 8% sevoflurane anaesthesia. *Anaesthesia* 2000; vol. 55; pp55-56
30. **Berry PD et al.** Severe Carbon Monoxide Poisoning during Desflurane Anesthesia. *Anesthesiology* 1999; vol. 90; pp613-616 (Case report)
31. **Frink EJ et al.** High Carboxyhemoglobin Concentrations Occur in Swine during Desflurane Anesthesia in the Presence of Partially Dried Carbon Dioxide Absorbents. *Anesthesiology* 1997; vol. 87(2); pp308-316
32. **Grogin WK et al.** Soda lime adsorption of isoflurane and enflurane. *Anesthesiology* 1985; vol. 62(1); pp60-64
33. **Knolle E et al.** Absorption of Carbon Dioxide by Dry Soda Lime Decreases Carbon Monoxide Formation from Isoflurane Degradation. *Anesthesia & Analgesia* 2000; vol. 91; pp456-461
34. **Lentz R.** Carbon Monoxide Poisoning During Anaesthesia Poses Puzzles. *Anesthesia Safety Foundation Newsletter* 1994; vol. 09; pp13-14
35. **Thwaites A et al.** Inhalation induction with sevoflurane: a double-blind comparison with propofol. *British Journal of Anaesthesia* 1997; vol 78; pp356-361